Search results
Results from the WOW.Com Content Network
RL is performed in people with liver cancer, both primary such as hepatocellular carcinoma and metastatic such as from colon adenocarcinoma.Surgical resection is considered the only curative treatment for liver cancer (other than liver transplantation for hepatocellular carcinoma) but it can only be performed in patients with sufficient remnant liver after resection (amongst other criteria).
Benign liver tumors generally develop on normal or fatty liver, are single or multiple (generally paucilocular), have distinct delineation, with increased echogenity (hemangiomas, benign focal nodular hyperplasia) or absent, with posterior acoustic enhancement effect (cysts), have distinct delineation (hydatid cyst), lack of vascularization or show a characteristic circulatory pattern ...
Consultant interventional radiologist Dr Brian Stedman said his team had performed 300 procedures in 100 patients whose form of eye cancer known as ocular melanoma had spread to the liver, called ...
The treatment was initially developed in the early 1970s. [1] The several types of hepatic artery treatments are based on the observation that tumor cells get nearly all their nutrients from the hepatic artery, while the normal cells of the liver get about 70-80 percent of their nutrients and 50% their oxygen supply from the portal vein, and ...
Since the mid-1980s, death rates from liver cancer have doubled. An estimated 41,000 new cases and 29,000 liver-cancer deaths are expected in 2017. Liver cancer is spreading with deadly intent
A liver metastasis is a malignant tumor in the liver that has spread from another organ that is affected by cancer. The liver is a common site for metastatic disease because of its rich, dual blood supply (the liver receives blood via the hepatic artery and portal vein). Metastatic tumors in the liver are 20 times more common than primary liver ...
The Liver Imaging Reporting and Data System (aka LI-RADS) is a quality assurance tool created and trademarked by the American College of Radiology in 2011 to standardize the reporting and data collection of CT and MR imaging patients at risk for hepatocellular carcinoma (HCC), or primary cancer of the liver cells. [1]
Nearly a third of patients with advanced liver cancer who received a personalized vaccine developed by Geneos Therapeutics along with an immunotherapy drug in a small, early trial saw their tumors ...